Open AccessCurrent Status and Progress of the Treatment of Limited-Disease Small Cell Lung Cancer
Author(s) -
Minghui Xu,
Jiaxiang Wang,
Zhigang Zhou,
Ling Lu,
Mengxuan Yang
Publication year - 2021
Publication title -
journal of clinical and nursing research
Language(s) - English
Resource type - Journals
eISSN - 2208-3693
pISSN - 2208-3685
DOI - 10.26689/jcnr.v5i5.2469
Subject(s) - medicine , radiation therapy , lung cancer , disease , chemotherapy , oncology , malignancy , metastasis , small cell lung carcinoma , targeted therapy , lung , cancer , small cell carcinoma , pathology
Small cell lung cancer (SCLC) is a common pathological type of primary lung cancer originating from the bronchial mucosa or gland. SCLC is characterized by rapid growth, high degree of malignancy, and early metastasis, which poses a great threat to patients’ safety and quality of life. SCLC can be divided into two stages: localized disease and extensive disease. For limited-disease small cell lung cancer (LD-SCLC), radiotherapy and chemotherapy are often used in clinical treatment. In recent years, there are several new advances in the clinical treatment of SCLC, including the improvement of radiotherapy and chemotherapy methods, compatibility of first-line and second-line drugs, as well as immune-targeted therapy. This article discusses the current status of clinical treatment and the research progress of LD-SCLC in the past five years.